Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?

References

• Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, et al. Well differentiated gastric tumors/carcinomas. Neuroendocrinology 2006;84:158–64.
   PubMed Web of Science ®Google Scholar
• Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, et al. Enets Consensus Guidelines for the management of patients with gastroduodenal neoplasm. Neuroendocrinology 2012;95:74–87.
   PubMed Web of Science ®Google Scholar
• Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010;17:909–18.
   PubMed Web of Science ®Google Scholar
• Rindi G, Arnold R, Bosman FT, Capella C, Kilmstra DS, Kloppel G, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In Bosman FT, et al. editors. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010. pp 13–14.
   Google Scholar
• Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988;41:185–200.
   PubMed Web of Science ®Google Scholar
• Merola E, Sbrozzi-Vanni A, Panzuto F, D’ Ambra G, Di Giulio E, Pilozzi E, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012;95:207–13.
   PubMed Web of Science ®Google Scholar
• Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1,009 cases from the literature. Medicine 2004;83:43–83.
   PubMed Web of Science ®Google Scholar
• Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992;33:1275–9.
   PubMed Web of Science ®Google Scholar
• Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999;116:532–42.
   PubMed Web of Science ®Google Scholar
• Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994–1006.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003;12:153–72.
   PubMed Web of Science ®Google Scholar
• Borch K, Ahren B, Ahlman H, Falkmer S, Granérus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005;242:64–73.
   PubMed Web of Science ®Google Scholar
• Lahner E, Pilozzi E, Esposito G, Galli G, Annibale B. Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge. Scand J Gastroenterol 2014;49:506–10.
   PubMed Web of Science ®Google Scholar
• Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011;56:931–50.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf 2002;1:29–38.
   PubMedGoogle Scholar
• Waldum HL, Qvigstad G. Proton pump inhibitors and gastric neoplasia. Gut 2007;56:1019–20.
   Google Scholar
• Fiocca R, Mastracci L, Attwood SE, Ell C, Galmiche JP, Hatlebakk J, et al. LOTUS trial collaborators. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012;36:959–71.
   PubMed Web of Science ®Google Scholar
• Eslami L, Nasseri-Moghaddam S. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med 2013;16:449–58.
   PubMed Web of Science ®Google Scholar
• Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010;16:2323–30.
   PubMed Web of Science ®Google Scholar
• Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. “The updated Sydney System”. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–81.
   PubMed Web of Science ®Google Scholar
• McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010;26:624–31.
   PubMed Web of Science ®Google Scholar
• Jianu CS, Fossmark R, Viset T, Qvigstad G, Sørdal O, Mårvik R, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012;36:644–9.
   PubMed Web of Science ®Google Scholar
• Haga Y, Nakatsura T, Shibata Y, Sameshima H, Nakamura Y, Tanimura M, et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci 1988;43:253–7.
   Google Scholar
• Dawson R, Manson JM. Omeprazole in oesophageal reflux disease. Lancet 2000;18:1770–1.
   Google Scholar
• Jianu CS, Lange OJ, Viset T, Qvigstad G, Martinsen TC, Fougner R, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012;47:64–7.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA background. Omeprazole Magensium (Prilosec 1 TM) Astra Zenza with proctor and Gamble. For the Joint Meeting of the Nonprescription Drugs Advisory Commitee and the Gastrointestinal Drugs Advisory Commitee; 20 October 2000.
   Google Scholar
• Rao SS, Nayak KS, Swarnalata G, Goyal DN, Rao KP, Mitros FA. Gastric carcinoid associated with ranitidine in a patient with renal failure. Am J Gastroenterol 1993;88:1273–4.
   Google Scholar
• Nakamura T, Igarashi H, Ito T, Jensen RT. Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example. World J Clin Cases 2014;2:608–13.
   Google Scholar
• Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005;19:1610–12.
   PubMedGoogle Scholar
• Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El-Serag H. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther 2011;33:829–36.
   PubMed Web of Science ®Google Scholar
• Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012;36:37–47.
   PubMed Web of Science ®Google Scholar
• Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Bloemena E, Nelis GF, Festen HP, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:605–12.
   Google Scholar
• Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci 2007;52:2482–9.
   PubMed Web of Science ®Google Scholar
• Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Håkanson R, et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Dig Dis Sci 1995;40:50S–62S.
   PubMed Web of Science ®Google Scholar
• Abraham NS. Proton pump inhibitors: potential adverse effects Curr Opin Gastroenterol. 2012;28:615–20.
   Google Scholar
• Bakke I, Qvigstad G, Brenna E, Sandvik AK, Waldum HL. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand 2000;169:29–37.
   PubMedGoogle Scholar
• Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986;35:42–55.
   PubMed Web of Science ®Google Scholar
• Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmacology and toxicology of omeprazole with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl 1986;118:31–8.
   Google Scholar
• McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology 2009;137:20–2.
   PubMed Web of Science ®Google Scholar
• Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut 1992;33:1303–6.
   PubMed Web of Science ®Google Scholar
• Bordi C, D’Adda T, Azzoni C, Pilato FP, Caruana P. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 1995;19:S8–19.
   PubMed Web of Science ®Google Scholar
• Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005;152:443–8.
   Google Scholar
• Sjoblom SM, Sipponen P, Karonen SL, Jarvinen HJ. Mucosal argyrophil endocrine cells in pernicious anaemia and upper gastrointestinal carcinoid tumours. J Clin Pathol 1989;42:371–7.
   PubMed Web of Science ®Google Scholar
• Helgadóttir H, Metz DC, Yang YX, Rhim AD, Björnsson ES. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Dig Liver Dis 2014;46:125–30.
   PubMedGoogle Scholar
• Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341–8.
   PubMed Web of Science ®Google Scholar
• Choudhry U, Boyce HWJr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998;110:615–21.
   PubMed Web of Science ®Google Scholar
• Graham DY, Genta RM. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep 2008;10:543–7.
   PubMedGoogle Scholar
• Dayal Y. Hyperplastic proliferations of the ECL cells. Yale J Biol Med 1992;65:805–25.
   PubMed Web of Science ®Google Scholar
• Solcia E, Rindi G, Fiocca R, Villani L, Buffa R, Ambrosiani L, et al. Distinct patterns of chronic gastritis associated with carcinoid and cancer and their role in tumorigenesis. Yale J Biol Med 1992;65:793–804.
   Google Scholar
• Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.Aliment Pharmacol Ther. 2000;14:651–68.
   Google Scholar
• Torbenson M, Lee JH, Cruz-Correa M, Ravich W, Rastgar K, Abraham SC, et al. Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis. Mod Pathol 2002;15:718–23.
   PubMed Web of Science ®Google Scholar
• D’Adda T, Keller G, Bordi C, Höfler H. Loss of heterozygosity in 11q13-14 regions in neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999. 79:671–7.
   Google Scholar